Nanobody-Based CD19/CD20 Tandem Dual CAR-T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma Early Phase 1
Summary
NIH registered a new Early Phase 1 clinical trial (NCT07546630) evaluating the safety and efficacy of Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell therapy for the treatment of relapsed/refractory B-cell lymphoma. The single-arm study will assess this novel tandem dual-targeting approach. This registration provides public visibility into an investigational CAR-T cell therapy program targeting both CD19 and CD20 antigens simultaneously.
“This is a single arm study to evaluate the safety and efficacy of Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell therapy for Relapsed/Refractory B-Cell Lymphoma”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
NIH published a new Early Phase 1 clinical trial registration (NCT07546630) for a nanobody-based CD19/CD20 tandem dual CAR-T cell therapy targeting relapsed/refractory B-cell lymphoma. The single-arm study will evaluate both safety and preliminary efficacy of this dual-targeted approach. This registration makes the trial publicly available on ClinicalTrials.gov, fulfilling requirements for transparency in human subjects research. For pharmaceutical companies and clinical investigators developing CAR-T or other cellular therapy programs, this registration illustrates the continued exploration of multi-antigen targeting strategies in hematologic malignancies. Sponsors and investigators should ensure all applicable clinical trial registrations are current and accurately reflect protocol amendments.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell Lymphoma
Early Phase 1 NCT07546630 Kind: EARLY_PHASE1 Apr 23, 2026
Abstract
This is a single arm study to evaluate the safety and efficacy of Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell therapy for Relapsed/Refractory B-Cell Lymphoma
Conditions: Relapsed/Refractory B-Cell Lymphoma
Interventions: CD19/CD20 Tandem Dual CAR-T
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.